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ABSTRACT The plasma membrane H-ATPase (Pma1) is an essential fungal protein
and a proposed target for new antifungal medications. The compounds in a small-
molecule library containing 191,000 commercially available compounds were
screened for their ability to inhibit Saccharomyces cerevisiae plasma membranes con-
taining Pma1. The overall hit rate was 0.2%, corresponding to 407 compounds.
These hit compounds were further evaluated for ATPase selectivity and broad-
spectrum antifungal activity. Following this work, one Pma1 inhibitor series based
on compound 14 and analogs was selected for further evaluation. This compound
series was able to depolarize the membrane and inhibit extracellular acidiﬁcation in
intact fungal cells concomitantly with a signiﬁcant increase in intracellular ATP lev-
els. Collectively, we suggest that these effects may be a common feature of Pma1
inhibitors. Additionally, the work uncovered a dual mechanism for the previously
identiﬁed cationic peptide BM2, revealing fungal membrane disruption, in addition
to Pma1 inhibition. The methods presented here provide a solid platform for the
evaluation of Pma1-speciﬁc inhibitors in a drug development setting. The present in-
hibitors could serve as a starting point for the development of new antifungal
agents with a novel mode of action.
KEYWORDS ATPase, antifungal agents, drug development, membrane proteins
Fungal infections affect 25% of the population, with superﬁcial infections of the skinand nails representing the most common type. In a survey of women (age 16 years
and older, n  6,000), up to 49% had been diagnosed with vulvovaginal candidiasis
(VVC), depending upon their ethnic origin, and approximately 20% of those women
experienced recurrent VVC in a 12-month follow-up period (1), with a pronounced
impact on quality of life. Invasive fungal infections are less common but of much
greater concern because they are associated with extremely high mortality rates (20 to
90%) (2). The most common invasive fungal infections are caused by the yeasts Candida
and Cryptococcus spp., followed by the molds Aspergillus and Mucor spp. Key areas of
concern in the treatment of invasive fungal infections with the current antifungal
medications include delays in diagnosis and the identiﬁcation of the speciﬁc patho-
genic species, intrinsic and acquired drug resistance, inconvenient drug administration,
safety, and tolerability issues with prolonged use. For these reasons, there is a major
unmet need for new antifungal agents (3).
The fungal plasma membrane H-ATPase has long been recognized to be a
promising antifungal target (4–6). The proton pump is essential for fungal growth, as
shown by knockout studies (7). The PMA1 gene encodes the H-ATPase, and the pump
is referred to as Pma1. The fungal cell is dependent on Pma1 creating an electrochem-
ical gradient across the plasma membrane, which is used by other transporters to
energize the uptake of ions and nutrients. Pma1 pumps protons from the cytosol to the
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exterior of the cell, energized by ATP hydrolysis. In this regard, fungal cells are
fundamentally different from human cells, where the plasma membrane potential is
created by the Na,K-ATPase (8).
Pma1 belongs to the type III family of P-type ATPases. The related human ATPases,
Na,K-ATPase, Ca2-ATPase (sarcoplasmic endoplasmic reticulum Ca2-ATPase
[SERCA]), and H,K-ATPase, belong to the type II family. All mammalian ATPases
share less than 30% amino acid sequence identity with Pma1. In contrast, the fungal
H-ATPase appears to be relatively conserved across the fungal kingdom (the amino
acid sequence similarity is generally 70 to 90%). The high level of conservation seen for
Pma1 warrants efforts to identify a speciﬁc Pma1 inhibitor with broad-spectrum anti-
fungal activity.
Within the last 35 years, a number of nonspeciﬁc compounds have been evaluated
as Pma1 inhibitors. To date, only a few Pma1 inhibitors, such as ebselen and the
peptide BM2, have been demonstrated to inhibit the growth of living fungal cells at
concentrations in the low micromolar range (4, 5, 9–12). Omeprazole is an inhibitor of
the human H,K-ATPase and has also been evaluated as an inhibitor of Pma1 (4).
Studies have shown that single mutations in the proposed binding site in Pma1 greatly
alter the growth-inhibitory effects of omeprazole (4). Omeprazole requires an acid
activation step to inhibit Pma1, and fungal growth inhibition is pH dependent. For full
growth inhibition of Saccharomyces cerevisiae, 430 M omeprazole is required at pH 3
(4), making it a low-potency antifungal compound.
The classical P-type ATPase inhibitor, vanadate, does not inhibit living cells due to
a lack of membrane penetrability. Ebselen is known to inhibit the mammalian H,K-
ATPase (13) and the Ca2-ATPase ATP6 of Plasmodium falciparum (PfATP6), in addition
to Pma1 (14). Due to the reactivity of ebselen with protein thiols, it is believed to target
several enzymes and modify a range of biological activities (15).
Natural products, such as tellimagrandin II (16) and the immunoprotein lactoferrin
(17), inhibit Pma1. Tellimagrandin II potently inhibits the growth of S. cerevisiae but not
that of Candida albicans. Lactoferrin exhibits antifungal activity against both S. cerevi-
siae and C. albicans at concentrations in the low micromolar range.
BM2 is a cationic peptide which potently inhibits Pma1 in an ATP hydrolysis assay
(50% inhibitory concentration [IC50]  0.5 M) (10). It displays greater than 90% fungal
growth inhibition at 0.63 M and pH 7.3 and at 5 M and pH 7.0. At concentrations
above the MIC for S. cerevisiae, BM2 also inhibits the Na,K-ATPase and HEp-2 cell
growth and causes blood cell lysis. BM2, ebselen, and vanadate have been selected as
comparators to the compounds characterized in this work.
In the present study, selected compounds were screened for their ability to inhibit
ATP hydrolysis by measuring the formation of free phosphate ions, corresponding to
inhibition of Pma1 under the assay conditions used. The identiﬁed inhibitors were
tested for their effects on the membrane potential, the intracellular ATP concentration,
extracellular medium acidiﬁcation, and fungal growth inhibition.
RESULTS
Screening and evaluation of 191,000 compounds for Pma1 inhibition. A large
library of small-molecule compounds was employed with the aim of ﬁnding novel
Pma1 inhibitors. In total, 191,000 library compounds were screened using the ATP
hydrolysis assay. An overview of the screening cascade is presented in Fig. 1. Com-
pounds (at a ﬁnal concentration of 20 M) inhibiting Pma1 enzymatic activity by
greater than 50% were regarded as hits in this study. All 407 hits were then counter-
screened for their activity against Na,K-ATPase and SERCA in order to distinguish
Pma1-speciﬁc compounds from general P-type ATPase inhibitors. All hits were screened
for potential antifungal activity against S. cerevisiae and C. albicans.
After evaluating the 407 hits, a selection of compounds was repurchased and
reevaluated for Pma1 inhibition and antifungal activity. These steps were undertaken to
conﬁrm the structural identity of the library compounds and to ensure that no
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compound degradation had occurred during the library storage period. The structures
of a selected number of these hits are presented in Fig. 2.
Evaluation of Pma1 inhibitors. Several interesting compounds with Pma1-
inhibitory activity (IC50  25 M) were identiﬁed through the library screening (Table
1). However, a number of these compounds, compounds 1, 2, 3, 6, 9, 11, and 12, were
poor antifungal compounds, with their MICs being above 150 M for several of the
Candida spp. tested (Table 1). Compounds 4 and 8 were also poor antifungal com-
pounds, with their MICs being 38 M, which was the highest concentration tested
due to poor compound solubility in dimethyl sulfoxide (DMSO). The precipitation of
several of these compounds observed in the fungal growth medium may partially
FIG 1 Overview of library screening. Hits were tested for selectivity for the two mammalian ATPases SERCA and Na,K-ATPase
as well as antifungal activity against Candida albicans and Saccharomyces cerevisiae. From this, several promising Pma1
inhibitors were identiﬁed, with compound 14 being the most promising candidate.
FIG 2 Structures of selected Pma1 inhibitors identiﬁed in the library screening.
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explain their lack of antifungal activity (Table 1). Unfortunately, several of these
compounds that lacked antifungal activity were the compounds that were selective for
Pma1 rather than SERCA and Na,K-ATPase. Compounds 5, 7, 10, and 13 were all
potent Pma1 inhibitors (IC50 25 M) with antifungal activity but were generally more
potent against the mammalian ATPases than against Pma1 or equally potent against
both the mammalian ATPases and Pma1. The most promising hit from the screen was
compound 14, a pyrido-thieno-pyrimidine, whose structure is shown in Fig. 3, together
with the structures of selected analogs of compound 14. Compound 14 was the
only compound more potent against Pma1 than against the mammalian ATPases
and which displayed a broad spectrum of antifungal activity against both yeasts
and molds (Table 1).
Additionally, 48 commercially available analogs were purchased for this study, and
all of these analogs shared the common motif shown in Fig. 3. Eight of these analogs
had an IC50 of less than 20 M for Pma1. Compound 14 and four of the most potent
or selective commercial analogs were chosen for further characterization (Fig. 3; Tables
2 to 5) in parallel with BM2, vanadate, and ebselen. Compound 17 was chosen as a
negative control because it had a scaffold similar to that of compound 14 but weak
Pma1 inhibition, probably due to the lack of an important lipophilic interaction in the
R1 position (ethyl versus n-butyl in compounds 17 and 14, respectively).
The four most potent analogs had a low level of Pma1 selectivity (Table 2), with
compound 18 being the most selective, exhibiting approximately 3- to 4-fold greater
selectivity toward Pma1 than toward SERCA or Na,K-ATPase. Compounds 15, 16, and
19 were more potent than compound 14 but had no selectivity for Pma1. All of the
compounds exhibited antifungal activity against both Candida and Aspergillus spp.
(Table 3), as well as a reduction in their activity on the viability/proliferation of
mammalian Hep-G2 cells (Table 4). In our hands, BM2 was 8-fold more selective for
Pma1 over Na,K-ATPase inhibition but had no selectivity toward SERCA. Further-
more, BM2 inhibited the growth of S. cerevisiae and C. albicans but had no effect on
mammalian Hep-G2 cells.
To determine if the observed antifungal activity was caused by Pma1 inhibition or
another mechanism, a range of additional assays was performed. Following glucose
activation of Pma1, subsequent proton extrusion leads to acidiﬁcation of the buffer
surrounding the cells. Inhibitors which prevent this extracellular acidiﬁcation likely act
through Pma1 inhibition, although these observations alone cannot discriminate be-
TABLE 1 ATP hydrolysis data and growth inhibition for identiﬁed Pma1 inhibitors from the library screeninga
Compound
IC50 (M) MIC (M)
Pma1 Na,K-ATPase SERCA C. albicans C. parapsilosis C. tropicalis C. glabrata A. fumigatus
1b 0.040 0.035 13.2 0.91 17.5 4.7 150c 150 150 150 150
2 2.1 1.3 105 105 150d NA NA NA NA
3 2.5 2.5 105 105 150e 150 150 150 150
4b 3.7 0.7 15.0 7.2 4.1 0.2 13d 38 12 38 38
5b 4.4 0.6 1.3 0.3 0.46 0.04 6.5f 7.5 7.5 5.8 75
6b 5.0 3.0 3.5 3.7 3.4 0.6 150d 150 150 150 150
7b 5.5 0.3 5.8 0.8 3.8 0.6 7.3d 8.2 26 4.7 150
8 6.9 2.0 105 105 38d 38 38 38 38
9 9.2 1.0 105 105 150d 150 150 150 150
10b 9.4 1.7 105 3.4 1.8 88 116 15 12 99
11 12.8 5.0 30.3 2.4 15.7 2.0 150d 150 150 150 150
12 15.5 8.1 58.7 40.2 105 12e 150 150 150 150
13 22.6 12.4 30.6 11.1 22.0 3.0 23 47 150 31 NA
14 13.7 2.0 18.4 2.1 42.0 8.0 36 24 24 41 75
aStructures are shown in Fig. 2. For IC50, data are from 2 to 3 experiments. For MICs, data are from 2 to 5 experiments. NA, not available.
bThe ATP hydrolysis assay was performed at pH 6.5 for Pma1 and pH 7.4 for Na,K-ATPase and SERCA. For all other compounds, the ATP hydrolysis assay was
performed at pH 7 for all ATPases.
cCompound precipitation was observed in the growth medium at concentrations down to 15 M.
dCompound precipitation was observed in the growth medium at concentrations down to 48 M.
eCompound precipitation was observed in the growth medium at concentrations down to 150 M.
fCompound precipitation was observed in the growth medium at concentrations down to 75 M.
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tween direct or indirect Pma1 inhibition (e.g., via membrane disruption). The acidiﬁca-
tion of the external medium is measured within a few minutes after compound
addition. Thus, compounds which cause fast plasma membrane disruption indirectly
affect proton transport and appear to be inhibitors of the acidiﬁcation process. How-
FIG 3 Structure of compound 14 and analogs.
TABLE 2 Effects of compound 14 and analogs on ATPase activitya
Compound
IC50 (M) for ATP hydrolysis
S. cerevisiae
Pma1
C. albicans
Pma1 Na,K-ATPase SERCA
14 13.7 2.0 17.0 0.9 18.4 2.1 42.0 8.0
15 5.9 0.2 6.3 0.5 4.1 0.6 4.5 0.0
16 7.8 0.6 9.5 1.0 9.1 1.0 11.1 0.0
17 106.7 18.2 150.7 6.2 333 333
18 18.5 4.3 22.9 2.0 85.7 26.6 69.5 6.9
19 7.3 1.0 8.7 0.5 5.5 1.8 4.4 0.3
BM2 1.2 0.1 0.9 0.2 10.4 2.7 1.1 0.0
Vanadate 0.25 0.01 0.23 0.05 0.006 0.001 10.4 2.4
Ebselen 0.92 0.15 0.51 0.04 0.16 0.01 0.12 0.00
aExperiments were performed at pH 7, and standard deviations (n  2) are given. Rabbit Ca2-ATPase
(SERCA1a) and porcine kidney Na,K-ATPase were used.
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ever, amphotericin B, a marketed antifungal which forms pores in the fungal mem-
brane, did not inhibit extracellular acidiﬁcation in the assay time frame of 12 min (Table
5). Compound 14 and its analogs inhibited the acidiﬁcation process at concentrations
similar to the IC50 for Pma1 in the ATP hydrolysis assay (Tables 2 and 5), which supports
the direct inhibition of Pma1. BM2 was slightly more potent in inhibiting the acidiﬁ-
cation process than inhibiting the puriﬁed Pma1 enzyme in the ATP hydrolysis assay
(Tables 2 and 5). The IC50 of ebselen for C. albicans was found to be 11 M, in
agreement with the previously reported value of 14 M (18).
The membrane potential decreases upon Pma1 inhibition without changes in
membrane integrity. A striking feature of the fungal cell membrane is the very high
membrane potential generated by Pma1. It has been measured to be 175 mV within
the fungal species Neurospora crassa (19). This value is signiﬁcantly higher than that
observed in mammalian cells, where the membrane potential is typically measured to
be 65 to 85 mV. The N. crassa measurements were performed on the large hypha
of this mold species with patch clamp electrodes, a setup which is technically difﬁcult
to reproduce on smaller cells, such as those of S. cerevisiae. To further demonstrate
Pma1 inhibition in living fungal cells, image cytometry was employed to investigate
membrane potential changes and membrane integrity upon compound exposure.
Membrane depolarization was assessed with the ﬂuorescent probe bis-(1,3-dibutyl-
barbituric acid) trimethine oxonol [DiBAC4(3)], which is only able to enter cells with a
decreased membrane potential. Simultaneously, propidium iodide (PI) was used to distin-
guish betweenmembrane depolarization and general membrane permeabilization, since PI
only enters cells with permeable cell membranes.
S. cerevisiae cells exposed to compound 14 yielded an elevated DiBAC4(3) signal
after 5 min of exposure, while only a minimal increase of the PI signal was observed
(Fig. 4A to C and Fig. S1). After 15 or 30 min of exposure, the sizes of both DiBAC4(3)-
positive cell populations and DiBAC4(3)- and PI-positive cell populations had increased.
These observations suggest that cells were ﬁrst depolarized prior to the membrane
integrity becoming compromised, thus allowing PI to enter the cells. After 30 min of
exposure to compound 14, only 16% of the cells remained both PI and DiBAC4(3)
negative, 44% were DiBAC4(3) positive and PI negative, and 39% were both PI and
TABLE 3 Antifungal activities of compound 14 and analogs against yeast and mold species
Compound
MIC (M) for growth inhibition
S. cerevisiae C. albicans C. parapsilosis C. tropicalis C. glabrata A. fumigatus A. ﬂavus
14 7.5 36 24 24 41 75 75
15 1.5 4.8 15 47 15 15 24
16 3.2 15 15 28 11 15 47
17 47 150 150 150 150 150 150
18 24 75 24 58 41 75 75
19 3.7 6 3.7 3.7 3.7 12 12
BM2 4.7 15 26 4.7 150 150 150
Vanadate 750 750 750 750 750 750 750
Ebselen 7.5 7.5 24 11 7.5 24 24
TABLE 4 Effects of Pma1 inhibitors on Hep-G2 cells
Compound EC50 (M) for Hep-G2 cells at 24 h
14 2.3 0.0
15 2.8 0.1
16 2.6 0.9
17 5.8 1.1
18 3.6 1.1
19 24.2 0.5
BM2 100
Vanadate 500
Ebselen 10.7 7.0
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DiBAC4(3) positive. Only 0.7% of the cells were PI positive but DiBAC4(3) negative. In the
DMSO control sample, 92% of the cells were both PI and DiBAC4(3) negative.
The most potent antifungal analog of compound 14 was compound 19, and this
compound was also evaluated with imaging cytometry at concentrations of 5 and 15
M. Similarly to compound 14, exposure of cells to compound 19 also resulted in two
large populations of DiBAC4(3)-positive and PI-negative cells and DiBAC4(3)- and PI-
positive cells after 30 min of exposure.
BM2 exposure led to a marked increase in the PI-positive population within 5 min,
indicating rapid effects on membrane integrity (Fig. 4A and Fig. S1). However, we also
observed an increase in the DiBAC4(3) signal after 15 or 30 min in BM2-treated cells. Given
TABLE 5 Effects of Pma1 inhibitors on medium acidiﬁcation in S. cerevisiae and
C. albicansa
Compound
IC50 (M) for acidiﬁcation
S. cerevisiae C. albicans
14 11.2 2.7 6.6 2.5
15 1.7 0.1 1.6 0.0
16 7.6 3.4 3.4 1.6
17 39.6 10.3 19.1 1.7
18 12.5 1.1 8.8 0.4
19 2.3 0.1 2.3 0.5
BM2 0.2 0.0 0.5 0.1
Vanadate 40 40
Ebselen 7.6 0.0 9.4 2.1
AMB 75 75
aThe IC50 was determined to be the concentration which resulted in 50% inhibition of medium acidiﬁcation
normalized to the response from glucose-activated versus non-glucose-activated cells. AMB, amphotericin B.
IC50 with standard deviations (n  2 to 3) are indicated.
FIG 4 Effects of inhibitors on membrane potential and membrane integrity in S. cerevisiae. (A) Bar chart of the cumulative percentage
of cells that were DiBAC4(3) positive or negative and PI positive or negative, as deﬁned by the quadrants in panel B. Cells were treated
with compound 14, 17, 19, or BM2 or CCCP at 5, 15, or 150 M for 5, 15, or 30 min (as indicated). Error bars indicating SEMs are shown
in only one direction for clarity. (B) Scatter plot of cells treated with 1% DMSO for 30 min (control). (C) Scatter plot of cells treated with
15 M compound 14 for 30 min. Representative scatter plots for all conditions are shown in Fig. S1 in the supplemental material. RFU,
relative ﬂuorescent units.
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the effects on membrane integrity, it is difﬁcult to attribute the increased DiBAC4(3) signal
to direct Pma1 inhibition. The protonophore carbonyl cyanide m-chlorophenylhydrazone
(CCCP) had an effect on the PI and DiBAC4(3) signals similar to that of compounds 14 and
19. Compound 17, which had an IC50 of 107 M for puriﬁed S. cerevisiae Pma1, did not
increase the DiBAC4(3) signal in S. cerevisiae cells, and the PI signal was not signiﬁcantly
increased.
iATP levels increase upon Pma1 inhibition. Pma1 requires ATP to energize proton
transport out of the fungal cell. A decrease in the intracellular ATP (iATP) levels
indirectly affects the activity of Pma1. To rule out the possibility that the Pma1
inhibition observed was indirectly caused by decreased ATP levels, we determined iATP
levels after compound exposure (Fig. 5A to C). Treatment of S. cerevisiae and C. albicans
cells with compound 14 led to a signiﬁcant increase in iATP levels (200% and 1,500%,
respectively) compared to those for the untreated control. When S. cerevisiae cells were
exposed to compound 14 in the presence of oligomycin, an ATP synthase inhibitor,
iATP levels remained comparable to those for control cells. Compound 19 behaved in
a manner similar to that for compound 14, leading to a signiﬁcant increase in iATP
levels in S. cerevisiae and C. albicans. Treatment with BM2 also led to a large increase
in ATP levels (1,100%) compared to that for the control cells. When S. cerevisiae cells
were treated with BM2 and oligomycin together, the increase in iATP levels was limited
to 300%. However, the addition of oligomycin to BM2-treated C. albicans cells did not
alter the iATP level compared to that in cells treated with BM2 alone. Treatment with
oligomycin alone, CCCP, vanadate, and the low-potency Pma1 inhibitor compound 17
had minimal effects on iATP levels compared to those found after treatment with
compounds 14, 19, and BM2. Ebselen could not be tested, as it inhibited the luciferase
enzyme used in the iATP assay. The increase in iATP levels in C. albicans for compounds
14, 19, and BM2 was shown to be dose responsive, with all compounds producing a
maximum iATP level of about 500 nM (per well) at the highest concentrations of
inhibitors tested (Fig. 5C). The half-maximal (50%) effective concentrations (EC50) were
calculated to 13, 7, and 2 M for compounds 14, 19, and BM2, respectively. Interest-
ingly, these values were fairly close to the IC50 for the Pma1 enzyme from C. albicans
of 17, 9, and 0.9 M, respectively.
DISCUSSION
In the initial screening process, we identiﬁed a number of selective and relatively
potent Pma1 inhibitors; however, many lacked antifungal activity. One interesting
compound series which exhibited both antifungal activity and an afﬁnity for Pma1 over
the mammalian ATPases was identiﬁed and further characterized. An initial understand-
FIG 5 Pma1 inhibitors increase iATP levels in S. cerevisiae (A) and C. albicans (B and C). The total cellular ATP concentrations were determined after
30 min of treatment. The mean data (n  3) with the SD are indicated as the percent change compared to that for the untreated control sample
(1% DMSO) (A and B) or as the concentration (in nanomolar) of iATP (C). olig., oligomycin A (at 40 M in all panels). *, P  0.05 compared to the
untreated control by unpaired t test; **, P  0.01 compared to the untreated control by unpaired t test.
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ing of the structure-activity relationship for this series was established on the basis of
such relationships for commercially available compounds.
The compound 14 series, containing a pyrido-thieno-pyrimidine group, was consid-
ered especially interesting since small changes to the scaffold yielded signiﬁcant
changes in the inhibitory properties toward the three ATPases tested. Our data suggest
a direct interaction with the ATPases rather than an interaction via compound aggre-
gates, which is a common false-positive mechanism (20, 21). 4-Aminoalkylamino de-
rivatives of pyrido[3=,2=:4,5] thieno[3,2-d]pyrimidine have been shown to interact with
a number of molecular targets, including phosphodiesterase IV, and to have potential
use in the treatment of asthma and chronic obstructive pulmonary disease (22; S. L. M.
Pages and M. J. Taltavull, U.S. patent application, June 2006) and in the control of tumor
necrosis factor alpha (TNF-) release (23) and to have beta2 adrenoreceptor agonist
activity (24). Additionally, diverse biological activities, such as anticonvulsant (25–27)
and neurotropic (28, 29) activities, have been ascribed to compounds similar to those
presented here. To our knowledge, this is the ﬁrst description of pyrido-thieno-
pyrimidines as inhibitors of P-type ATPases. The Pma1-inhibitory activity was conﬁrmed
both through the inhibition of acidiﬁcation of the extracellular medium and through
the demonstration of membrane depolarization but not an immediate loss of integrity
by the DiBAC4(3) assay.
DiBAC4(3) and PI are frequently used as stains for dead or dying cells. However,
DiBAC4(3) enters the cells due to a loss of membrane potential, whereas PI enters the
cells due to a loss of membrane integrity. By using a short time frame (5 to 30 min) and
observing individual cells, DiBAC4(3) can be used to estimate changes in membrane
potential, while costaining with PI reveals when the membrane loses its integrity.
Previously, DiBAC4(3) (30) and other ﬂuorescent probes used to measure membrane
potential, such as 3,3-dipropylthiacarbocyanide iodide) [diS-C3(3)] (31), have been used
to estimate changes in membrane potential. To our knowledge, DMM-11, a competitive
inhibitor of Mg2-ATP, is the only other Pma1 inhibitor which has previously been
shown to depolarize the fungal plasma membrane (12).
The protonophore CCCP was used as a positive control in the membrane potential
study; however, it required high concentrations to overcome the proton excretion
induced by Pma1 and depolarize the membrane. CCCP has previously been shown to
affect the mitochondrial membrane and, thereby, the supply of ATP (32). In this study,
treatment with CCCP resulted in limited changes to the iATP levels in S. cerevisiae and
C. albicans (Fig. 5). Treatment with the ATP synthase inhibitor oligomycin did not result
in a large signiﬁcant change in iATP levels, in agreement with earlier observations by
Andrés et al. (17). These data suggest that fungal cells can compensate for ATP synthase
inhibition for short periods of time under these conditions.
Compounds 14, 19, and BM2 gave rise to a large signiﬁcant increase in iATP levels,
while compound 17 (a low-potency Pma1 inhibitor) gave rise to a substantially lower
increase. Increases in iATP levels have previously been reported with exposure to
omeprazole (36% increase) in S. cerevisiae (33) and lactoferrin (600% increase) in C.
albicans (17). Both omeprazole and lactoferrin are described to be Pma1 inhibitors,
although omeprazole is not fully capable of inhibiting extracellular acidiﬁcation (33).
We suggest that an increased iATP level is attributable to Pma1 inhibition, considering
that Pma1 is the major consumer of ATP in the cell and is thought to consume 20 to
50% of the cellular ATP (34). Therefore, unused ATP accumulates in the cell when Pma1
is inhibited. Increased iATP levels have also been observed in Pma1 mutants with partial
defects in pumping activity (35), supporting the hypothesis that increased iATP levels
are a consequence of Pma1 inhibition.
Ebselen was found to inhibit not only Pma1 but also the mammalian ATPases SERCA
and Na,K-ATPase. Given that ebselen has previously been reported to inhibit PfATP6
and the H,K-ATPase (13, 14), this compound is likely an unspeciﬁc P-type ATPase
inhibitor.
In our hands, BM2 exhibited less selectivity for S. cerevisiae (ATCC 9763) Pma1 over
porcine Na,K-ATPase than the previously reported 50-fold selectivity of S. cerevisiae
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(T48) Pma1 over canine Na,K-ATPase, determined when the IC50 of S. cerevisiae (T48)
Pma1 and canine Na,K-ATPase were compared (10). Furthermore, we observed no
selectivity of BM2 for Pma1 over SERCA. BM2 affected the membrane potential, but
given the rapid and severe effects on overall membrane integrity, it is unclear if the
depolarization was directly caused by Pma1 inhibition. Increased cell permeation of
rhodamine 6G (Rh6G) was also previously observed in an Rh6G efﬂux assay with 10
M BM2, which further supports our observations that BM2 compromises membrane
integrity (10). Despite the decreased membrane integrity, our results suggest that Pma1
was inhibited, as indicated by the observed large increase in iATP levels.
Oligomycin did not completely prevent the rise in iATP levels of S. cerevisiae cells
treated with BM2. Furthermore, iATP levels in C. albicans cells were signiﬁcantly
changed in response to BM2 exposure, regardless of the presence of oligomycin. We
therefore speculate that the inhibition of ATP synthase by oligomycin is slower than the
accumulation of iATP resulting from the actions of BM2. We speculate that the increase
in iATP levels due to Pma1 inhibition, together with BM2’s additional membrane-
disruptive effects, facilitates the killing of fungal cells.
Together, our data support the suggestion that BM2 operates via a dual mechanism
where both the fungal membrane and the fungal proton ATPase are affected, leading
to fungal growth inhibition and cell death. Greater selectivity toward SERCA and the
Na,K-ATPase is likely required. Special attention should be paid to possible mem-
brane interactions, as BM2 affects fungal membrane integrity and has previously been
linked to low-level hemolysis and detectable toxicity in HEp-2 cells (10). On the basis of
the membrane potential and integrity results, the compound 14 series has a mode of
action different from that of BM2. The antifungal effect of compound 14 appears to be
more a direct consequence of Pma1 inhibition as compared to BM2, as the latter affects
both Pma1 activity and the membrane integrity. As expected for an inhibitor of the
essential and conserved Pma1 protein, the compound 14 series has a broad spectrum
of antifungal activity, inhibiting the growth of all Candida and Aspergillus spp. tested.
This is in contrast to BM2, which has poor activity against Candida glabrata and the
Aspergillus spp.
Some of the compounds identiﬁed during the library screen inhibited Pma1 on an
enzymatic level; however, this did not always translate into antifungal activity. There are
several plausible explanations for this lack of translation. Fungal cells contain a complex
cell wall, which may serve as an impermeable barrier to compound entry. The com-
pounds might not be able to cross the cell membrane due to aggregate formation,
leading to false-positive hits in the enzymatic assay. False-positive hits may also result
from unspeciﬁc protein inhibition activity in a homogeneous assay setup (20, 21).
Finally, the chemical properties of the compounds must be taken into consideration, as
the possibility that some of the compounds tested precipitated when approaching
concentrations required for their effect cannot be ruled out.
In this study, novel compounds with Pma1-inhibitory properties were identiﬁed and
direct inhibition of Pma1 in fungal cells was conﬁrmed by a decrease in the plasma
membrane potential, while membrane integrity was preserved. Encouragingly, com-
pounds 14 and 18 displayed selectivity against the mammalian ATPases, with both
showing 3-fold selectivity toward SERCA and compound 18 showing 4-fold selectivity
toward the Na,K-ATPase. Compound 19 was interesting, as it displayed a 3-fold
toxicity window between C. albicans and Hep-G2 cells, despite it being an unselective
ATPase inhibitor. However, the fungal growth and Hep-G2 cell assay conditions differed
signiﬁcantly by the presence of 10% fetal bovine serum (FBS) in the Hep-G2 cell assay
mixture. In C. albicans growth assays, a 10-fold increase in the MIC value of compound
19 occurred when 10% FBS was added to the assay mixtures (see Table S2 in the
supplemental material). This suggests signiﬁcant protein binding of compound 19. The
reduced toxicity window observed when fungal and Hep-G2 cell assays were run under
comparable conditions also highlights that selectivity for Pma1 over mammalian
ATPases should have high priority in any future Pma1 drug development.
The collection of methods presented herein is especially useful in antifungal drug
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development targeting Pma1. They can reveal whether inhibition of Pma1 enzymatic
activity can be translated into Pma1 inhibition in living cells, while simultaneously
ruling out several indirect mechanisms. Future directions for study should include the
synthesis of more analogs with the aim of optimizing the potency and speciﬁcity of the
compounds, thereby improving the toxicity window toward Hep-G2 cells. In conclusion,
there is a requirement for improvement of both the physical and chemical properties
as well as the selectivity for Pma1 over mammalian ATPases before a new Pma1-
targeting drug candidate can be developed.
MATERIALS AND METHODS
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless stated otherwise. Saccharo-
myces cerevisiae RS72 was used for puriﬁcation of the plasma membranes which were used in the library
screening. S. cerevisiae (ATCC 9763) was also used for puriﬁcation of plasma membranes and for all assays
except the initial library screening.
Puriﬁcation of ATPases. Plasma membranes containing Pma1 were isolated from S. cerevisiae RS72
cells containing the full-length cDNA of the S. cerevisiae plasma membrane H-ATPase isoform PMA1
under the control of the PMA1 promoter, as described in reference 16.
A 100-ml overnight culture in YPD medium [10 g/liter yeast extract (BD, Sparks, MD), 20 g/liter Bacto
peptone (BD), 20 g/liter D-()-glucose] was transferred to 1 liter YPD medium and grown at room
temperature and 150 rpm for 18 h for wild-type S. cerevisiae (ATCC 9763) and 7 h for C. albicans. The cells
were harvested and washed in Milli-Q H2O by centrifugation at 3,360 	 g. The cells were glucose
activated by the addition of 10% D-()-glucose for 10 min while shaking. The cells were then centrifuged
at 3,360 	 g for 3 min and frozen. Cells (60 to 80 g, wet weight) were then disrupted by bead beating
(BioSpec, Bartlesville, OK) and processed as described in reference 16 to prepare the plasma membranes.
For C. albicans only, microsomes were prepared, as the sucrose gradient step did not provide additional
purity. All batches were validated by ATPase hydrolysis activity, pH optimum, and orthovanadate
sensitivity.
Rabbit sarcoplasmic reticulum membranes containing sarcoplasmic endoplasmic reticulum Ca2-
ATPase (SERCA) were kindly provided by Claus E. Olesen and Jesper V. Møller, Aarhus University, and
prepared as described in reference 36. Porcine kidney Na,K-ATPase was kindly provided by Natalya
Fedosova, Aarhus University, and prepared as described in reference 37.
Measurement of ATP hydrolysis. The protein activity levels were determined by measuring the
amount of free phosphate produced from the ATP hydrolysis reaction. The assay was performed as
described in reference 16. Each well contained ATPase enzyme, 2 l of inhibitor (usually in the range of
333 to 0.01 M) dissolved in dimethyl sulfoxide (DMSO) (Duchefa Biochemie, Haarlem, The Netherlands),
and an assay buffer dependent on the enzyme for a ﬁnal volume of 60 l. Possible compound
precipitation in the assay buffer was monitored using a Nephelostar plate reader measuring turbidity,
and the information was taken into account in the IC50 determination. Pma1 assay buffer consisted of 20
mM 3-(N-morpholino)propanesulfonic acid (MOPS)–NaOH, pH 6.5 or 7.0, 8 mM MgSO4, 50 mM KNO3 (a
vacuolar ATPase inhibitor), 25 mM sodium azide (a mitochondrial ATPase inhibitor), and 250 M sodium
molybdate (an acid phosphatase inhibitor). SERCA buffer consisted of 9 mM MOPS-NaOH, pH 7, 2.7 mM
MgCl2, 90 M CaCl2, and 72 mM KCl. Na,K-ATPase buffer consisted of 30 mM MOPS-NaOH, pH 7, 40
mM NaCl, 4 mM MgCl2, and 20 mM KCl. The concentration of protein was adjusted to obtain a signal of
the optical density at 860 nm (OD860) of between 0.5 and 1.0 in the untreated samples (for all Pma1
batches, 1 to 2 g/well; for SERCA and Na,K-ATPase, 0.1 to 0.2 g/well). BM2 (RRRFWWFRRR-NH2,
D-form amino acids) was custom synthesized by Peptide 2.0 (Chantilly, VA).
Library screening. Libraries of compounds in a 96-well plate format were screened for Pma1
inhibition with the puriﬁed S. cerevisiae RS72 plasma membranes using the ATP hydrolysis assay at pH
6.5. All compounds were diluted in DMSO. The libraries were commercially available from the following
suppliers: Key Organics (13,681 compounds; Cornwall, UK), ChemBridge (63,042 compounds; San Diego,
CA), ChemDiv Inc. (34,000 compounds; San Diego, CA), InterBioScreen (24,072 compounds; Chernogo-
lovka, Russia), Specs (36,854 compounds; Zoetermeer, The Netherlands), Asinex (9,021 compounds;
Rijswijk, The Netherlands), and ComGenex (10,000 compounds; Budapest, Hungary). The CAS numbers of
selected compounds are as follows: compound 1, 375352-86-6; compound 2, 845990-59-2; compound 3,
496771-56-3; compound 4, 372174-76-0; compound 5, 488107-35-3; compound 6, 847044-59-1.
Fungal growth inhibition assay. The following fungal isolates were used: Saccharomyces cerevisiae
ATCC 9763, Candida albicans SC5314, Candida parapsilosis ATCC 22019, Candida tropicalis Ct016, Candida
glabrata ATCC 90030, Aspergillus fumigatus ATCC 13073, and Aspergillus ﬂavus ATCC MYA-1005. Frozen
stocks of yeast isolates in glycerol (ﬁnal concentration, 20%) were prepared by growing the cells to log
phase in YPD medium at 30°C and 150 rpm. Frozen stocks of mold spores were prepared by harvesting
spores from 7-day-old potato glucose agar plates in phosphate-buffered saline, 0.1% Tween 80 and
aliquoting these spores in the presence of glycerol (ﬁnal concentration, 20%). The cells were stored
at 80°C. The cells or spores were thawed and diluted to a ﬁnal concentration of 0.5 	 105 to 2.5 	 105
CFU/ml in sterile Milli-Q H2O. In a 96-well plate, the fungal suspension was added to an equal volume of
2	 RPMI medium (20.8 g/liter RPMI 1640 medium [catalog number R6504; Sigma-Aldrich], 0.33 M MOPS,
36 g/liter glucose adjusted to pH 7.0 with KOH) to which an inhibitor compound had been added, thus
giving a ﬁnal DMSO concentration of 1.5% in 1	 RPMI medium. The plate was incubated for 20 to 24 h
at 34°C (72 h for molds), and the OD490 was measured on a Victor X5 (PerkinElmer) plate reader. Mold
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growth assay plates were also visually inspected. The MIC was deﬁned as the lowest concentration
inhibiting the visual growth of the microorganism. Standard errors were typically below 5%.
Hep-G2 cell viability assay. In a tissue culture-treated 96-well plate (catalog number 655180;
Grenier), 10,000 human hepatocyte Hep-G2 cells (catalog number 85011430; Sigma-Aldrich) were plated
in 200 l growth medium (Eagle minimal essential medium; catalog number M2279; Sigma-Aldrich), 2
mM L-glutamine (catalog number 03-020-1B; Biological Industries), 1% nonessential amino acids (catalog
number XC-E1154/100; Biosera), 10% fetal bovine serum (catalog number BI-04-007-1A; Biological
Industries) and incubated overnight at 37°C in 5% CO2. On the next day, fresh growth medium plus 2 l
compound in DMSO was added. The plate was incubated for a further 24 h at 37°C in 5% CO2. The
medium was replaced with 100 l freshly prepared 0.5 mg/ml 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-
5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide, sodium salt, solution (catalog number X4251;
Sigma-Aldrich) in RPMI 1640 medium (catalog number R7509; Sigma-Aldrich) with 3.83 g/ml phenazine
methosulfate (catalog number P9625; Sigma-Aldrich) and incubated for 2 to 3 h at 37°C in 5% CO2. The
color reaction was measured on a Victor X5 plate reader (PerkinElmer) by determination of the OD450 and
the half-maximal (50%) effective concentration (EC50) was calculated.
Medium acidiﬁcation assay. Frozen stocks of C. albicans and S. cerevisiae were transferred to YPD
agar plates and incubated overnight at 34°C. On the next day, the cells were suspended and washed
twice in 50 mM KCl, pH 6.7, after pelleting of the cells by centrifugation at 3,000 	 g for 5 min. The cells
were then starved overnight at 4°C in the KCl solution. The cell suspension (ﬁnal OD600 of 0.19), an
inhibitor in DMSO (1.5%), and 1.3 g/ml dextran-ﬂuorescein isothiocyanate (molecular weight, 40,000;
catalog number FD40S; Sigma-Aldrich) were then mixed before initiation of the assay by the addition of
2% D-()-glucose to a ﬁnal assay volume of 200 l. The pH drop was then monitored by determination
of the ﬂuorescent signal with excitation at 485 nm and emission at 538 nm on a Fluoroskan Ascent plate
reader (Thermo Fisher Scientiﬁc) for 12 min. The rate of medium acidiﬁcation was calculated on the basis
of the slope of the drop in ﬂuorescence.
Membrane potential and integrity assay. Cells were transferred from frozen stocks to 3 ml of YPD
medium and grown overnight at 30°C and 150 rpm. The culture was diluted to an OD600 of 0.15 and
grown for 3 to 4 h at 30°C and 150 rpm to an OD600 of 0.5 to 0.7. The cells were pelleted by centrifugation
at 2,000 	 g for 2 min and washed in buffer A (100 mM MOPS and 1 mM KCl adjusted to pH 7.0 with
Trizma base). The washing procedure was repeated, and the cells were resuspended in buffer A to an
OD600 of 0.2. Fifty microliters of buffer A containing 3.3 g/ml propidium iodide (PI; catalog number
P1304MP; Thermo Fisher Scientiﬁc) and 1 g/ml DiBAC4(3) (catalog number D8189; Sigma-Aldrich) was
mixed with 50 l the S. cerevisiae cell suspension in buffer A and transferred to a 96-well plate with 1 l
of inhibitor in DMSO, and the components were mixed.
Approximately 30 l sample was transferred to an A2 glass slide (ChemoMetec, Allerod, Denmark),
and the slide was incubated at 30°C before the cells were counted on a NucleoCounter NC-3000
cytometer (ChemoMetec). Five thousand cells were counted per experiment with an exposure time of
1,000 ms. A dark ﬁeld was used as the masking channel to select the yeast cells. The DiBAC4(3) channel
(excitation, 530 nm; emission, 675/75 nm) and the PI channel (excitation, 630 nm; emission, 740/60 nm)
were used to measure the membrane potential and membrane integrity, respectively. To account for
the ﬂuorescent spillover from the PI channel to the DiBAC4(3) channel, 15% compensation was
applied. In all experiments, 1.9% compensation was used to compensate for the DiBAC4(3)-to-PI
spillover. The results were analyzed using NucleoView software (ChemoMetec). Only cells with a
pixel size of 10 to 40 were included in the analysis, thus avoiding analysis of noncell artifacts.
Carbonyl cyanide m-chlorophenylhydrazone (CCCP) was used as a positive control for decreased
membrane potential, and lysis buffer was used to validate lost membrane integrity.
Intracellular ATP. S. cerevisiae and C. albicans cells were grown and washed as described above for
the membrane potential and integrity assay and resuspended in SG medium (0.7% yeast nitrogen base
without amino acids [BD], 50 mM succinic acid adjusted to pH 7 with Trizma base) to OD600 of 0.2 and
0.1, respectively. One hundred microliters of an S. cerevisiae or C. albicans cell suspension and 1 l
compound in DMSO were incubated for 30 min. Twenty-ﬁve microliters of the suspension was then
transferred to a black 96-well plate containing 25 l BacTiter-Glo reagent (Promega, Madison, WI) and
incubated for 15 min in the dark. The luminescence was read on SpectraMax X5 (Molecular Devices,
Sunnyvale, CA) plate reader with a 10 s of shaking and a 0.5 s integration time. Standard curves at 10,
100, and 1,000 nM ATP were performed with every experiment.
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